Log in
Enquire now
‌

US Patent 10391168 Anti-CD70 combination therapy

Patent 10391168 was granted and assigned to University of Bern on August, 2019 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors
Patent abstract

Provided are methods and compositions for the treatment of a BCR-ABL1 related disorder (e.g., chronic myelogenous leukemia) using a therapeutic combination of a WNT signaling pathway inhibitor and a BCR-ABL1 tyrosine kinase inhibitor.

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like US Patent 10391168 Anti-CD70 combination therapy

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo
By using this site, you agree to our Terms of Service.